Search Results Search Sort by RelevanceMost Recent Policy Forum Apr 2019 How Should Engineered Nanomaterials Be Regulated for Public and Environmental Health? David B. Resnik, JD, PhD Minimizing and managing risks of ENMs means considering whether and when existing legal frameworks offer sufficient protection. AMA J Ethics. 2019;21(4):E363-369. doi: 10.1001/amajethics.2019.363. Letter to the Editor Oct 2017 Response to “What Should Physicians Do When They Disagree, Clinically and Ethically, with a Surrogate’s Wishes?” Petros Ioannou, MD, MSc, PhD Understanding the religious background of patients and their surrogates is essential to providing patient-centered care at the end of life. AMA J Ethics. 2017;19(10):1051-1053. doi: 10.1001/journalofethics.2017.19.10.corr3-1710. Policy Forum Dec 2019 How Should Gene Editing Be Managed by Risk Managers? David Sine, D.Bioethics Little claims data exists upon which to make informed decisions about loss control or to draw upon when developing risk mitigation strategies. AMA J Ethics. 2019;21(12):E1059-1064. doi: 10.1001/amajethics.2019.1059. Letter to the Editor Jul 2020 Response to “How Should Global Tobacco Control Efforts Be Prioritized to Protect Children in Resource-Poor Regions?” A Deliberate Public Policy Plus Naivety at Best Alain Braillon, MD, PhD Do the WHO and health professionals simply fail to do their job adequately? AMA J Ethics. 2020;22(7):E639-642. doi: 10.1001/amajethics.2020.639. Letter to the Editor Jul 2020 Response to “A Deliberate Public Policy Plus Naivety at Best” Stella Aguinaga Bialous, DrPH and Yvette van der Eijk, PhD Debate continues on how to frame tobacco and nicotine product regulation from a children’s rights perspective. AMA J Ethics. 2020;22(7):E643-644. doi: 10.1001/amajethics.2020.643. Policy Forum Feb 2022 ¿Cómo deberían los clínicos tácticos ayudar a hacer un uso más justo de la fuerza? David Callaway, MD and Faroukh Mehkri, DO AMA J Ethics. 2022;E133-139. doi: 10.1001/amajethics.2022.133. Policy Forum Feb 2022 ¿Cómo se debería equilibrar el riesgo para el personal táctico con los requerimientos clínicos y ética de rescate? Mollie V. Williams, MD, MPH and Olaitan Ajisafe, MD, PharmD AMA J Ethics. 2022;E140-144. doi: 10.1001/amajethics.2022.140. Policy Forum May 2022 What Should Dietary Supplement Oversight Look Like in the US? Elizabeth Richardson, MSc, Farzana Akkas, MSc, and Amy B. Cadwallader, PhD Statutory limitations prevent the FDA from effectively regulating dietary supplements and have generated numerous calls for reform. AMA J Ethics. 2022;24(5):E402-409. doi: 10.1001/amajethics.2022.402. Policy Forum May 2022 Which Features of Dietary Supplement Industry, Product Trends, and Regulation Deserve Physicians’ Attention? Amy B. Cadwallader, PhD and AMA Council on Science and Public Health Illegal, fraudulent, adulterated, or improperly labeled products should be regarded as sources of possible clinical and ethical harm to patients. AMA J Ethics. 2022;24(5):E410-418. doi: 10.1001/amajethics.2022.410. Policy Forum Feb 2022 How Should Tactical Clinicians Help Make Use of Force More Just? David Callaway, MD and Faroukh Mehkri, DO A public health approach to violence is required to help 21st-century policing evolve. AMA J Ethics. 2022;24(2):E133-139. doi: 10.1001/amajethics.2022.133. Pagination Current page 1 Page 2 Page 3 Next page Next › Last page Last »
Policy Forum Apr 2019 How Should Engineered Nanomaterials Be Regulated for Public and Environmental Health? David B. Resnik, JD, PhD Minimizing and managing risks of ENMs means considering whether and when existing legal frameworks offer sufficient protection. AMA J Ethics. 2019;21(4):E363-369. doi: 10.1001/amajethics.2019.363.
Letter to the Editor Oct 2017 Response to “What Should Physicians Do When They Disagree, Clinically and Ethically, with a Surrogate’s Wishes?” Petros Ioannou, MD, MSc, PhD Understanding the religious background of patients and their surrogates is essential to providing patient-centered care at the end of life. AMA J Ethics. 2017;19(10):1051-1053. doi: 10.1001/journalofethics.2017.19.10.corr3-1710.
Policy Forum Dec 2019 How Should Gene Editing Be Managed by Risk Managers? David Sine, D.Bioethics Little claims data exists upon which to make informed decisions about loss control or to draw upon when developing risk mitigation strategies. AMA J Ethics. 2019;21(12):E1059-1064. doi: 10.1001/amajethics.2019.1059.
Letter to the Editor Jul 2020 Response to “How Should Global Tobacco Control Efforts Be Prioritized to Protect Children in Resource-Poor Regions?” A Deliberate Public Policy Plus Naivety at Best Alain Braillon, MD, PhD Do the WHO and health professionals simply fail to do their job adequately? AMA J Ethics. 2020;22(7):E639-642. doi: 10.1001/amajethics.2020.639.
Letter to the Editor Jul 2020 Response to “A Deliberate Public Policy Plus Naivety at Best” Stella Aguinaga Bialous, DrPH and Yvette van der Eijk, PhD Debate continues on how to frame tobacco and nicotine product regulation from a children’s rights perspective. AMA J Ethics. 2020;22(7):E643-644. doi: 10.1001/amajethics.2020.643.
Policy Forum Feb 2022 ¿Cómo deberían los clínicos tácticos ayudar a hacer un uso más justo de la fuerza? David Callaway, MD and Faroukh Mehkri, DO AMA J Ethics. 2022;E133-139. doi: 10.1001/amajethics.2022.133.
Policy Forum Feb 2022 ¿Cómo se debería equilibrar el riesgo para el personal táctico con los requerimientos clínicos y ética de rescate? Mollie V. Williams, MD, MPH and Olaitan Ajisafe, MD, PharmD AMA J Ethics. 2022;E140-144. doi: 10.1001/amajethics.2022.140.
Policy Forum May 2022 What Should Dietary Supplement Oversight Look Like in the US? Elizabeth Richardson, MSc, Farzana Akkas, MSc, and Amy B. Cadwallader, PhD Statutory limitations prevent the FDA from effectively regulating dietary supplements and have generated numerous calls for reform. AMA J Ethics. 2022;24(5):E402-409. doi: 10.1001/amajethics.2022.402.
Policy Forum May 2022 Which Features of Dietary Supplement Industry, Product Trends, and Regulation Deserve Physicians’ Attention? Amy B. Cadwallader, PhD and AMA Council on Science and Public Health Illegal, fraudulent, adulterated, or improperly labeled products should be regarded as sources of possible clinical and ethical harm to patients. AMA J Ethics. 2022;24(5):E410-418. doi: 10.1001/amajethics.2022.410.
Policy Forum Feb 2022 How Should Tactical Clinicians Help Make Use of Force More Just? David Callaway, MD and Faroukh Mehkri, DO A public health approach to violence is required to help 21st-century policing evolve. AMA J Ethics. 2022;24(2):E133-139. doi: 10.1001/amajethics.2022.133.